Matches in Wikidata for { <http://www.wikidata.org/entity/Q105089083> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q105089083 description "clinical trial" @default.
- Q105089083 description "ensayo clínico" @default.
- Q105089083 description "ensayu clínicu" @default.
- Q105089083 description "klinisch onderzoek" @default.
- Q105089083 description "клінічне випробування" @default.
- Q105089083 description "临床试验" @default.
- Q105089083 name "Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" @default.
- Q105089083 name "Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" @default.
- Q105089083 type Item @default.
- Q105089083 label "Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" @default.
- Q105089083 label "Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" @default.
- Q105089083 prefLabel "Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" @default.
- Q105089083 prefLabel "Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" @default.
- Q105089083 P1050 Q105089083-88922B9F-1DBA-4069-BBF3-E0D056896A79 @default.
- Q105089083 P1132 Q105089083-7D0FF6C1-9C07-4E54-940E-8CC7FEF48289 @default.
- Q105089083 P1476 Q105089083-059DF1E6-70AC-496E-A808-1A7AED00193F @default.
- Q105089083 P2899 Q105089083-160E365C-7D2F-4605-B199-05F6F20CFEF6 @default.
- Q105089083 P3098 Q105089083-44686B21-8ED0-4C15-A224-B0F435F052CA @default.
- Q105089083 P31 Q105089083-781C190B-FE4E-4651-AD1B-0F6ED118C80B @default.
- Q105089083 P4844 Q105089083-38E494CB-FEBE-48DB-AA59-6307CBFBF2A9 @default.
- Q105089083 P580 Q105089083-506D327A-CB6C-4A80-94DC-0721FF34A706 @default.
- Q105089083 P582 Q105089083-6580BF4A-B1D0-4899-99B3-80B54389C394 @default.
- Q105089083 P6099 Q105089083-69AB5F66-212F-48A4-9944-0AC6E0DB3B4E @default.
- Q105089083 P8005 Q105089083-D6C80423-FC06-4B9D-B7B3-EC8402887C68 @default.
- Q105089083 P8363 Q105089083-EF97B085-3BEE-487D-B98A-BBF483187B34 @default.
- Q105089083 P1050 Q356033 @default.
- Q105089083 P1132 "+117" @default.
- Q105089083 P1476 "A Prospective, Non-randomized, Multicenter, Phase II Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Unresectable Recurrent or Metastatic Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" @default.
- Q105089083 P2899 "+18" @default.
- Q105089083 P3098 "NCT04609176" @default.
- Q105089083 P31 Q30612 @default.
- Q105089083 P4844 Q27262801 @default.
- Q105089083 P580 "2020-10-22T00:00:00Z" @default.
- Q105089083 P582 "2022-03-31T00:00:00Z" @default.
- Q105089083 P6099 Q42824440 @default.
- Q105089083 P8005 Q76649708 @default.
- Q105089083 P8363 Q78089383 @default.